Skip to main content
Clinical Trials/NCT00141583
NCT00141583TerminatedNot Applicable

The Renin-Angiotensin System in Essential Hypertension

St George's, University of London2 sites in 1 country11 target enrollmentStarted: April 2004Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
11
Locations
2
Primary Endpoint
Change in BP

Study Overview

Brief Summary

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Masking
None

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Essential Hypertension
  • SBP 140-159 mmHg
  • DBP 90-99 mmHg

Exclusion Criteria

  • Intolerance of or allergy to ACE Inhibitors or ARBS
  • Pregnant or Breastfeeding
  • Pre-menopausal women
  • Uncontrolled cardiac or renal failure
  • Diabetes mellitus

Outcomes

Primary Outcomes

Change in BP

Change in PRA and aldosterone

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials